Q4 revenue increased by 4% to £6.3bn, well in line with our expectations (all growth figures at CER unless specified). As expected, the HIV division reported solid growth (+51%), followed by Vaccines (+20%, -1% at pro-forma) and the Consumer Healthcare segment (+47%; +5% at pro-forma). The non-HIV pharma business continued to languish (-17%, -9% pro forma). Core operating profit declined by 18% to £1.4bn (10% pro forma; margin of 22%), with (before scrapping R&D) HIV margin im
